Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"The Pink Sheet" – Most Notable Stories Of 2010

Executive Summary

While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.

You may also be interested in...

Waxman Says Biosimilar Pathway Will Push Applicants To BLA

The outgoing chairman of the House Energy and Commerce Committee said the new abbreviated biosimilar pathway FDA is now formulating likely will not attract many applicants.

For PhRMA, There Is Good News And Bad News In The Mid-Term Elections

The anti-government intervention sentiment coming to Congress in January with the newly elected Republicans presents a tactical challenge to lobbying efforts by the Pharmaceutical Research and Manufacturers of America.

FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution

It didn't seem like deliberate choice to play good cop-bad cop, but Acting Office of Generic Drugs Director Keith Webber and Center for Drug Evaluation and Research Director Janet Woodcock offered a near textbook version of it at the recent Generic Pharmaceutical Association Fall Technical Conference.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts